USPTO serial 79403149
QUBIT PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 7, 2026
- Examiner
- KLUWE, CHERYL D
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with QUBIT PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
STEVEN J SOLOMON
STEVEN J SOLOMON TUCKER ELLIS LLP950 MAIN AVENUE, SUITE 1100CLEVELAND, OH 44113UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable and recorded computer software using artificial intelligence for visualization and modeling of molecules, molecular interactions, drug discovery, simulation of drug-target binding, and for the analysis of biomedical datasets; data acquisition and processing apparatus;; downloadable applications for mobile devices for visualization and modeling of molecules, molecular interactions, drug discovery, simulation of drug-target binding, and for the analysis of biomedical datasets; electronic databases recorded on computer media for use in the fields of cosmetics, health, medicine, pharmacology and the treatment of illnesses; data files in electronic format, downloadable, namely data sets containing data concerning cosmetics, health, medicine, pharmacology and the treatment of illnesses; scientific, technological and educational data sets in electronic form, downloadable; downloadable sound, video and audiovisual recordings featuring scientific, technological and educational information in the fields of cosmetics, health, medicine, pharmacology and the treatment of illnesses; downloadable and recorded software for conducting research; downloadable and recorded artificial intelligence and machine learning software for conducting scientific research in the cosmetic and medical fields; downloadable and recorded software for streaming scientific and technological content via the Internet and global communication networks; downloadable and recorded software for disseminating scientific and technological content to mobile digital electronic devices; downloadable and recorded scientific intelligence and monitoring software for visualization and modeling of molecules, molecular interactions, drug discovery, simulation of drug-target binding, and for the analysis of biomedical datasets; downloadable and recorded software for scientific and technological data research; downloadable computer software and applications using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in the development of pharmaceuticals; downloadable and recorded computer software, computer programs featuring algorithms for manipulating data input or received; data processing equipment; downloadable and recorded software for decision-making support; downloadable and recorded software for data analysis in the fields of cosmetics, health, medicine, pharmacology and the treatment of illnesses; downloadable and recorded software for data aggregation, analysis and processing integrating a collective work environment and for shared work and shared use of resources and data; downloadable and recorded software for planning, performing, integrating, optimizing and monitoring the research and development of new products, particularly new drugs; downloadable and recorded computer simulation software for planning, performance, integration, optimization and tracking of research and development of new products, particularly new drugs; downloadable and recorded collaborative software platforms for collaboration management, particularly in the scientific and technical fields; downloadable electronic publications, namely, research articles, scientific journals, white papers, reports, and conference proceedings featuring quantum computing applications, and artificial intelligence (AI) methodologies for research; all of the aforesaid goods being for use in connection with or relating to scientific research and research in the medical and pharmaceutical fields. | ABANDONED | — |
| 035 | Collection of information, particularly commercial and scientific information, namely, compilation of scientific, cosmetic, health, medical and pharmacology information into computer databases for business purposes; collection of data, namely, commercial, scientific, cosmetic and health data, for business purposes; Providing consumer product information to customers via the Internet; computerized database management; management of computerized files and records of molecules and formulations for medical and pharmaceutical use, as well as medicines and medical and pharmaceutical research; provision of business information services relating to data processing; providing commercial information from on-line databases; organization of business meetings, namely, business meeting planning for establishing commercial collaborations; computer data processing services; compilation of statistical data relating to medical research for business purposes; business networking services, namely, arranging and commercial management of business collaborations; business project management with respect to commercial business, featuring business research and business development collaborations; compilation of scientific and technical information into computer databases; business information and advice concerning all the aforesaid services; all the aforesaid services provided in connection with or relating to scientific research and the pharmaceutical and medical fields. | ABANDONED | — |
| 038 | Transmission of information and data by electronic communication networks; rental of access time to users of computer programs on data networks; rental of access time to platforms on the Internet enabling the consultation, analysis, exchange and sharing of data; rental of access time to databases in global computer networks; all the aforesaid services provided in connection with or relating to scientific research and the pharmaceutical and medical field. | ACTIVE | — |
| 042 | Scientific research and scientific analysis of molecules in the field of developing cosmetics and treatments and medicines; medical research services, namely, computerized testing and analysis of medical compounds, medicines and molecules with the purpose of discovering new treatments or improving and optimizing of existing treatments; design of technical and scientific studies, namely, design, and planning of scientific research studies; design, development, programming, configuration, installation, maintenance, updating and testing of algorithms and computer software, particularly for artificial intelligence, molecular modelling and molecular interactions modeling, and decision support; design, development, programming, configuration, installation, maintenance, updating and testing of algorithms and computer software and platforms that are used for consulting, analyzing, exchanging and sharing data, particularly in a collaborative work environment, for use in the fields of cosmetics, health, medicine, pharmacology and the treatment of illnesses; design, development, composition, updating and testing of new medicines and new medicine formulas all being scientific research; medical and scientific research for the development of pharmaceutical products for medical or veterinary use; computer database design and development, namely, designing databases for use in the fields of health, medicine, pharmacology and the treatment of illnesses; design of computer databases; development of computer platforms; scientific and technical project study being scientific study and research in the fields of medicine, pharmacology and the treatment of illnesses; conducting of engineering surveys; design, development and programming of artificial intelligence software for use in the fields of health, medicine, pharmacology and the treatment of illnesses; software design and development for data capture, input, extraction, processing, display and storage systems; consultancy in connection with computer technology; development of computer programs, namely, decision support software; Software as a Service (SaaS) services featuring software for processing and analyzing data in the fields of health, medicine, pharmacology and the treatment of illnesses; computer project management in the field of electronic data processing; hosting of digital content, namely, of computer databases, for others, in the fields of cosmetic, health, medicine, pharmacology and the treatment of illnesses; rental of computer software in the fields of cosmetic, health, medicine, pharmacology and the treatment of illnesses; platform as a service (PaaS) featuring computer software platforms for high performance or quantum computing, for pharmaceutical, medical and scientific research; provision of information relating to scientific technology, namely scientific research information in the field of pharmaceuticals; provision of temporary use of non-downloadable software for data processing and analysis; preparation of technical and scientific reports, namely, providing technical and scientific information in the field of medical research; scientific research services; research and development services relating to the processing of medical data for third parties; computer programming services for data analysis; pharmaceutical and drug active ingredient discovery services; organizing, coordinating, conducting and monitoring scientific research in the field of cosmetics, health, medicine, pharmacology and the treatment of illnesses; advanced product research, design and development in the field of artificial intelligence; research in the field of quantum computing services applied to pharmaceutical, medical and scientific research; compiling data for scientific research purposes in the pharmaceutical and medical fields; drug discovery services; advisory and information services relating to the aforesaid services; all the aforesaid services provided in connection with or relating to scientific research and the medical field. | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by QUBIT PHARMACEUTICALS
- Other trademarks owned by QUBIT PHARMACEUTICALS
- Other trademarks owned by QUBIT PHARMACEUTICALS
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 038
- Other trademarks in Class 042
- Similar marks named QUBIT PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 1, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 12, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 11, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 7, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 7, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 7, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 18, 2026 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Mar 18, 2026 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Mar 18, 2026 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Feb 12, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 27, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 5, 2025 | RFNP | REFUSAL PROCESSED BY IB | — |
| Nov 8, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Nov 7, 2025 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Nov 6, 2025 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Nov 6, 2025 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Jul 30, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jul 8, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 8, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 2, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 5, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 14, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 29, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 6, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 6, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 22, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 21, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 3, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 3, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |